Lv5
1500 积分 2024-03-05 加入
The landscape for radioligand therapies in oncology
5天前
已完结
From concept to clinic: Cutting-Edge advances steering the next wave of antibody–drug conjugates innovation
1个月前
已关闭
Navigating the Landscape of Resistance Mechanisms in Antibody–Drug Conjugates for Cancer Treatment
1个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
1个月前
已完结
Homogeneous multi-payload antibody–drug conjugates
1个月前
已完结
Targeting cancer with small molecule pan-KRAS degraders
2个月前
已完结
Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC
4个月前
已完结
Recent Advances in Peptide Linkers for Antibody-Drug Conjugates
4个月前
已完结
Enhancing the bystander effect of antibody-drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity
4个月前
已完结
Dual-payload antibody–drug conjugates: Taking a dual shot
4个月前
已完结
皖公网安备34019202002308
